REGN
Regeneron Pharmaceuticals, Inc.
Stock
$735.20+0.39 (+0.05%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $8.0B | $8.6B | $9.0B | $10.8B | $7.7B | $5.7B | $3.6B | $3.2B | $2.8B | $1.4B | $1.0B | $1.0B | $900M | $694M | $308M | $527M | $249M | $341M | $248M |
| Inventory | $3.1B | $3.2B | $3.1B | $2.6B | $2.4B | $2.0B | $1.9B | $1.4B | $1.2B | $726M | $399M | $239M | $129M | $70M | $29M | $17M | — | — | — |
| Current assets | $18.4B | $18.0B | $18.7B | $19.5B | $15.9B | $14.0B | $9.8B | $7.7B | $6.4B | $4.3B | $3.2B | $2.9B | $2.1B | $1.8B | $1.2B | $666M | $358M | $426M | — |
| Intangible assets | $1.3B | $1.3B | $1.1B | $1.0B | $916M | $6.7M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total assets | $41.7B | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B | $17.2B | $14.8B | $11.7B | $8.8B | $7.0B | $5.6B | $3.8B | $3.0B | $2.1B | $1.3B | $1.1B | $741M | — |
| Current liabilities | $5.5B | $4.4B | $3.9B | $3.4B | $3.1B | $3.9B | $2.7B | $2.1B | $1.4B | $1.1B | $1.2B | $811M | $655M | $299M | $164M | $148M | $109M | $94M | — |
| Long-term debt | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B | $0 | — | — | — | — | — | — | — | — | — | — | — |
| Total liabilities | $10.0B | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B | $6.1B | $3.7B | $3.0B | $2.6B | $2.5B | $2.0B | $1.3B | $999M | $835M | $838M | $562M | $344M | — |
| Shareholders' equity | $31.7B | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B | $11.0B | $11.1B | $8.8B | $6.1B | $4.4B | $3.7B | $2.6B | $2.0B | $1.2B | $486M | $528M | $397M | $422M |
| Shares outstanding | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 91.8M | 87.8M | — | — |
| Current ratio | 3.34 | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 | 3.59 | 3.18 | 6.01 | 7.37 | 4.49 | 3.28 | 4.55 | — |